This label expansion opens a new, underserved pediatric segment (ages 2-5) for ZORYVE, potentially driving incremental prescription volume and market share in pediatric psoriasis. Monitor upcoming quarterly earnings for commentary on pediatric adoption and any competitive responses from steroid-based alternatives. The approval also strengthens Arcutis' regulatory track record ahead of potential pipeline catalysts.
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 30 $26.22entry
- T+1 · 5mo ago −1.45%α −1.31% · $25.84
- T+5 · 4mo ago −0.57%α −1.18% · $26.07
- T+20 · 4mo ago +6.18%α +7.21% · $27.84
- T+60 · 8w ago +0.61%α −2.21% · $26.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arcutis Biotherapeutics received FDA approval to expand ZORYVE cream 0.3% for plaque psoriasis to children as young as 2 years old, the seventh FDA approval for ZORYVE in four years. This addresses a significant treatment gap in pediatric psoriasis, where limited steroid-free options existed for young children. The approval is based on a Phase 2 MUSE study and long-term extension data showing safety and efficacy consistent with adult/adolescent trials.
Key Facts
- FDA approved sNDA for ZORYVE cream 0.3% to treat plaque psoriasis in children down to age 2, including intertriginous areas
- Seventh FDA approval for ZORYVE in four years; first once-daily steroid-free topical approved for ages 2+ with plaque psoriasis
- Approval based on 4-week MUSE study (ARQ-151-216) in children ages 2-5 and 24-week open-label extension (ARQ-151-306)
- ZORYVE cream 0.3% already approved for adults and children down to age 6; this expansion adds ages 2-5
- ZORYVE is the #1 prescribed branded topical therapy across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis combined
Financial Impact
Expands addressable pediatric plaque psoriasis population by approximately 2-5 year age group; no specific revenue figures provided in release
Risk Factors
- Competition from existing topical steroids and emerging non-steroidal therapies in pediatric psoriasis
- Reimbursement and formulary access for the expanded pediatric indication may take time to materialize
- Real-world adoption by pediatric dermatologists and primary care physicians may be slower than expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319348 |
Track record
34 reports on ARQT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers